Author: healthcareonline7

I work for Transparency Market Research (TMR) a market intelligence company,
providing global business information reports and services. Our exclusive
blend of quantitative forecasting and trends analysis provides
forward-looking insight for thousands of decision makers. Our business
offerings represent the latest and the most reliable information
indispensable for businesses to sustain a competitive edge.
I use to write blogs related to healthcare industry which include
Biotechnology, Pharmaceuticals, Healthcare IT and Medical devices.

Elemental analysis is a process of detection and quantification of elemental compounds, molecular species and elements. This analysis technique is a part of analytical chemistry and can be qualitative and quantitative in nature. Sample types tested for trace elements comprises of aqueous, non-aqueous, organic and non-organic materials. For organic chemists, elemental analysis refers to CHNX analysis, which is used to determine the purity and structure of a compound. In this technique, a sample is burnt in excess of oxygen and thereby collecting combustion products like carbon dioxide, nitric acid and water. The masses of these products are used to determine composition of the sample. Ultra trace analysis and elemental trace analysis detection range from parts per million (ppm), to parts per billion (ppb) and parts per trillion (ppt) levels, using updated techniques and instruments. Some of the major technologies used for elemental analysis include inductively coupled plasma mass spectrometry, inductively coupled plasma optical emission spectrometry, X-ray Fluorescence and X-ray Diffraction among others.

Some of the key driving factors for elemental analysis market are increasing concern for food safety, increasing usage of X-ray fluorescence in clinical research and growing R&D funding in life sciences. Moreover, this technology has a wide range of application areas in different segments of industry and thus has a major market worldwide. There are other geographical drivers which are also responsible for the growth of the market. In addition, demand from emerging markets across India and China are expected to create opportunities for elemental analysis market in the future. However, high cost of elemental analyzers and urge for efficient professionals act as major restraints to the growth of the market.

Global elemental analysis market can be broadly classified on the basis of types, technology, applications and geography. By types, the market for elemental analysis is segmented into organic and inorganic. The market is divided by technology into destructive and non-destructive technologies. Moreover, elemental analysis has different application areas including food and beverage testing, life sciences, environment testing and geology among others.

Currently North America is dominating the market for elemental analysis in terms of revenue, followed by Europe and Asia-Pacific. The major factor responsible for immense development of elemental analysis market in North America is rapid technological advancement of this technique in various application areas, such as food and beverage, biotechnology, chemical and semiconductor industries among others. However, Asia Pacific is anticipated to grow at a significant rate in the future, primarily due to increasing awareness for elemental analysis in China and India coupled with rising demand from applied markets. Furthermore, strategic expansion by manufacturers in China and use of modern analysis technique in Chinese medicines are likely to develop the market for elemental analysis in Asia Pacific.

There are multiple drugs in the pipeline for opioid induced constipation treatment. Upon approval, these drugs will face little competition in this market which is largely untapped. There have not been many stable choices in the pharmaceutical industry for opioid induced constipation treatment over the recent past, but the continuous approval rate of highly targeted drugs is expected to provide a strong push to this market’s growth rate. This includes the PAMORA drugs that help treat OIC without intervening in the opioid’s action on the patient.

The number of patients suffering from opioid induced constipation is increasing across the globe. Close to 100 mn U.S. patients in 2013 were suffering from OIC, according to the American Academy of Pain Medicine. They added that this number is expected to increase as the number of people consuming opioid drugs increases. With a growing awareness of the commercial availability of a large variety of opioid drugs, people have resorted to using them for longer terms to treat chronic pains. This growing number of OIC patients – especially in North America – is expected to further drive the demand for opioid induced constipation treatment.

There is, however, the competition that opioid induced constipation treatment providers face from standard laxatives. Most healthcare organizations still consider standard laxatives as the first line of treatment for OIC. Additionally, the long term adverse effects of opioid induced constipation treatments have not completely been documented.

All in all, the global market for opioid induced constipation treatment is expected to be valued at US$731.2 mn by the end of 2016. Owing to a whopping CAGR of 31.2% from 2015 to 2023, this revenue is expected to reach US$4.8 bn by 2023.

North America has always taken up a large chunk of the global consumption of opioid induced constipation treatment drugs. By the end of 2023, North America alone is expected to generate US$4.05 bn of the global revenue from opioid induced constipation treatments. This region also leads in terms of growth rate of demand, owing to the large percentage of population that consumes opioid drugs and suffers from OIC. This comes from a high number of patients that are suffering from chronic diseases and are resorting to opioids.

Additionally, the penetration of opioid induced constipation treatments is very low in other regions as compared to North America. This could be the reason for the high disparity of consumption rates between regions. At the moment, North America dominates in terms of opioid consumption. According to the ASIPP, the U.S. alone consumes close to 80% of the global supply of opioids.

Till the end of 2016, chloride channel activators are expected to be the more popular drug class of opioid induced constipation treatments. This trend will continue for the coming years, but in time it is predicted that mu-opioid receptor antagonists will take the leading role among drug classes. A key reason for the popularity of chloride channel activators is the high level of sales of Amitiza ever since it was approved in 2013 and used specifically for opioid induced constipation treatment.

Over time, the growing number of mu-opioid receptor antagonists being approved and their greater efficacy over other drug classes is expected to push it to the top of the charts in terms of revenue generation before 2023. This drug class will also benefit from the increasing number of prescriptions being filed for opioid induced constipation treatments due to developments that reduce their side effects.

Smart healthcare products combined with IoT is redefining medical care for better treatment outcomes at reduced costs. The inclusion of IoT in smart healthcare products has a high degree of appeal for a spectrum of services which includes remote health monitoring, chronic diseases, fitness programs, and elderly care. In particular, this has high significance for treating critical care patients as patient data is easily accessible to medical personnel across several platforms at any given time.

The high-value advantages of smart healthcare products are resulting in stepping up of efforts from several governments and healthcare agencies to provide support for their adoption for quality healthcare. In particular, governments of developed nations are endorsing smart healthcare products to raise the quality of healthcare services for the nation’s population. In developing economies, rising GDP aiding the modernization of healthcare services is fueling the growth of smart healthcare products.

However, high costs associated with smart healthcare products is limiting their use for select services. As revealed by studies carried out by U.S. ONC, smart healthcare products if adopted by small healthcare organizations not only defeats time and cost-saving benefits but also damages their financial condition. Thus, smart healthcare products are suitable for large healthcare organizations.

The global smart healthcare products market is expected to rise at a CAGR of 8.84% between 2015 and 2023. This will result in the market’s valuation to increase from US$31.71 bn in 2016 to US$57.85 bn by 2023.

Due to the steady entry of small and medium sized companies, North America smart healthcare products market is expected to lead among other regional markets. Furthermore, as IT is the backbone of healthcare services in the region, they are increasingly being integrated with smart healthcare products to deliver high-quality patient care. An increasing rate of patients suffering from chronic diseases is also necessitating the use of remote monitoring devices for uninterrupted patient care. The region is expected to register a revenue contribution of US$21.09 bn to the global market by the end of 2023.

On the other hand, Asia Pacific is expected to dominate in terms of consumption of smart healthcare products. The region is heading towards digitization of services, including healthcare by means of government support and economic growth.

The inventory management application segment of the smart healthcare products market is expected to display a CAGR of 11.82% between 2015 and 2023. The increasing use of advanced RFID solutions and RFID smart cabinets in the healthcare industry is a major factor for the growth of this application segment. The inventory management application segment is expected to register substantial growth due to the enormous amount of data that needs to be recorded and stored by organizations. However, the application segment of health data storage and exchange is expected to be dominant in this market until 2023 due to a high volume demand worldwide.

Smart pills are displaying an exponential rise in demand and are expected to continue doing so until the end of the forecast period in 2023. Smart pills are expected to display a phenomenal 18.84% CAGR between 2015 and 2023. Meanwhile, the product segment of electronic health records is expected to dominant until 2023 registering a revenue contribution of US$39.61 bn over the period.

The field of genome engineering, the process of artificially introducing modification to the genetic content of an organism by introducing an artificially constructed piece of DNA of a specific composition into a recipient cell, has witnessed a significant rise in research activities in the past few years. Undertaken with the view of gaining larger clarity about the outcome of genome engineering experiments and finding newer applications of carefully controlled genetic experiments, the number of such research activities is rising at an immense pace.

Some of the most easily recognizable and highly popular applications of genome engineering practices are the use of genetically engineered microorganisms to produce vaccines and genetically modified crops. A vast variety of other applications of genome engineering are also being increasingly analyzed and put to use to develop organisms or living species with an improved genetic makeup.

Transparency Market Research estimates that the global genome engineering market will exhibit a remarkable 14.2% CAGR from 2015 through 2023, with market’s opportunity rising from US$2.30 bn in 2015 to an estimated US$7.21 bn by 2023.

Genome engineering practices find extensive usage across the academic field and industries such as agriculture, biotechnology, and pharmaceuticals. In 2014, biotechnology and pharmaceutical companies contributed nearly 58% of the market’s overall revenue. The significant rise in the use of genome engineering practices in therapeutics and drug discovery have contributed to the immense growth of this application segment. The trend is expected to remain strong over the report’s forecast period as well, with the extensive use of genome engineering in the pharmaceutical industry expected to drive the market significantly.

Applications of genome engineering in the academics sector emerged as the second largest contributor to the revenues of the global genome engineering market in 2014. Owing to the preliminary success achieved in a number of academic studies, the demand for genome engineering practices has significantly increased in the academic sector, chiefly for the production of mutants and treatment of genetic disorders. The vast global rise in prevalence of genetic disorders and a variety of cancers, the academic sector is expected to lead to stable demand for genome engineering practices in the next few years as well.

Vast Rise in Genome Research Activities to Help North America Retain Leading Position

Home to some of the world’s largest pharmaceutical and biotechnology companies, North America is one of the mist lucrative market’s for genome engineering. The region has witnessed a significant rise in research and development activities in the field of genetics and its applications across these industries. The North America genome engineering market held a valuation of US$1.27 bn in 2015 and is expected to continue to rise at a healthy pace over the report’s forecast period as well. The increasing demand for research dealing with the legal, ethical, and social implications of genome engineering will continue to lead to an increase in the number of genome engineering practices taking place in the region.

Over the report’s forecast period, Asia Pacific is expected to emerge as the most lucrative regional market for genome engineering. The regional market is expected to benefit from rising government incentives aimed at the development of the field in emerging economies and increased interest by companies in the region due to low research costs.

Cord blood banking refers to collection and preservation of blood derived from the umbilical cord, thus saved for future therapeutic and research applications. Umbilical cord blood is observed to be a potential source of progenitor cells, which can be used for reconstitution of tissue, organs and other functional areas. Cord blood transplantation is being recommended for a variety of diseases which include conditions such as leukemia, sarcoma, lymphoma, immune conditions and even metabolic disorders. Over the last two decades, the global stem cell therapeutics industry has experienced impressive growth. Stem cells are the progenitors of all hematopoietic cells that generate red and white blood cells and blood platelets. These cells can be isolated and further transferred to a patients suffering from serious blood disorders and other chronic conditions. Moreover, cord blood stem cells are observed to be convenient to harvest and can be stored for decades, their rejection rate is less than that of bone marrow transplant and possess low infection risk. Large and easy availability of cord blood units also widens the scope of transplant options, especially for patients with mixed ethnicity. However, cord blood banking market in LATAM is in process of evolution and expected to grow at significant rate due to favorable changes expected to carry out by revising government policies and regulations.

The LATAM cord blood banking market is be categorized on the type of storage option into public and private cord blood banking. High incidence of genetic disorders and better apprehension of such diseases due to availability of high end diagnostic services has been highly instrumental in rendering market dominance to private cord blood banking services. However, relatively high service charges for cord blood banking and the general opinion among physicians about less possibility of the use of such stored units may restrict the growth of private cord banking services market in a few countries of LATAM such as Brazil, Mexico, Argentina, Peru and others.

Advancement in stem cell therapy research has encouraged the practice of cord blood banking in Latin America due to rapidly increasing technological and infrastructural development in the region. Major countries such as Brazil, Mexico, and Colombia are focusing on expansion of cord blood bank networks. Most of the cord blood banks are supported by government funding. However, several private cord blood banks have already entered the market and many others are planning to enter the market in Latin America in the near future. Some of the established cord blood banks in Latin America also operate in the field of tissue engineering, non-invasive prenatal tests and stem cell development. Numerous countries in Latin America are on the verge of taking initiatives to decrease the drawbacks of public and private banking by implementing a hybrid model. The hybrid cord blood banking model is expected to involve storage of the sample in two portions. One portion is for the usage of the child or solely its close family member, while the other portion is stored as public donation.

The rapid increase in the number of injectable drugs to be approved recently has been a key contributor to the growth in demand for disposable syringes specifically, over other types of syringes. This is due to the growing number of patients afflicted with accidental needlestick injuries. Both factors thus work in tandem to create a staggering demand for disposable syringes and will continue to do so in the long term.

The number of disposable syringes being used has also increased due to the growth in point-of-care administration systems. These systems promote the self-administration of drugs, which can be easily done with modern disposable syringes with improved safety features.

The effective result of the above factors of influence on the market – along with a few others – for disposable syringes is expected to translate to a CAGR of 5.6% from 2015 to 2023. This market is expected to be valued above US$9.3 bn by the end of 2023 and close to US$6.5 bn by the end of 2016.

North America Remains Leading Disposable Syringe Consumer While Players Look to APAC for Bigger Opportunities

By the end of 2016, North America disposable syringe makers are expected to gain a revenue of US$3.9 bn, which is close to half of the total revenue earned on a global level. North America is expected to maintain its dominance over disposable syringes revenue till 2023, although it is expected to lose some percentage to the burgeoning Asia Pacific market. Europe will remain the second-largest region for disposable syringes till 2023. Both North America and Europe are showing a high demand for disposable syringes due to the growing number of injectable drugs in the market, improvements in syringe quality and safety through regulatory adherence, and the concern over a growing number of needlestick injuries.

China and India are expected to be the two key lucrative avenues for disposable syringes players in the near future, owing to their high population densities and growth in healthcare expenditures. A large part of this growth in demand for disposable syringes is attributed to the increasing number of government and private initiatives for conducting immunization drives across the countries. Additionally, the higher interest shown by North American and European players in these regions is expected to add to the quality of disposable syringes available in the market, further increasing their consumption rates.

Conventional disposable syringes have held the larger share by volume till now, and will be expected to hold the dominant share for a few more years. However, the segment is expected to lose its leading position to safety syringes which are gaining popularity at a rapid pace. Safety syringes already lead the market in terms of value. By 2023, safety syringes are expected to hold a revenue share of 84%.

Key reasons for the high accelerated growth rate shown by safety syringes is the absence of any safety mechanisms in conventional ones. Safety syringes help protect patients from needlestick injuries and are just as accurate and easy to use as conventional disposable syringes.

In response to the rising incidence of antibody diseases, Transparency Market Research (TMR) forecasts the global primary immunodeficiency market to surge at 6.1% CAGR between 2015 and 2023. Developed regions such as Europe and North America are predominantly contributing to the growth witnessed by this market. The consistent approval of novel therapeutic options for primary immunodeficiency diseases (PIDD) and extensive research and development investments by key players are likely to bolster opportunities for the market in the forthcoming years.

On the flip side, the absence of proper reimbursement and high cost of therapies will inhibit the market’s growth trajectory to an extent. Nevertheless, with favorable government policies and funding for research and development in biopharma and pharmaceuticals, growth prospects for the market seem quite promising.

TMR expects the global PIDD market to reach US$7.5 bn by the end of 2023, from a valuation of US$4.3 bn in 2014.

Collectively accounting for a share of 79.4% in the global PIDD market, North America and Europe emerged as the dominant regional segments in 2014. Among these regions, North America boasted the largest share of 56.2% in 2014, with the U.S. at the fore. As per TMR, the U.S. held over 80.2% of the PIDD market in North America in the same year. The nation is expected to continue demonstrating lucrative opportunities for the PIDD market through the forecast period.

Over the last couple of years, a persistently increasing prevalence of diseases such as selective IgA deficiency, IgG subclass deficiency, and common variable immune deficiency has been witnessed in North America. This has fuelled the uptake of PIDD therapeutics. However, the growing awareness pertaining to side-effects such as renal failure and allergic reactions frequently associated with the treatment could hamper the market’s growth to an extent.

The primary immunodeficiency diseases market in North America, which stood at US$2.4 bn in 2014, is expected to reach US$4.3 bn by the end of 2023. The market is therefore expected to rise at a CAGR of 6.4% during the period.

In Europe, the market is expected to gain from the increasing awareness regarding PIDD and favorable government support. The presence of companies such as Baxter International Inc., CSL Behring LLC, and Blotest Pharmaceuticals Corporation also supports the market’s expansion in the region. Apart from this, emerging nations in Asia Pacific also exhibit lucrative scope for the expansion of the PIDD market. The increasing willingness among people to spend on novel therapeutics augurs well for sales prospects of the market in Asia Pacific. The region currently holds only a moderate share in the market. However, in the near future the opportunities for sale of PIDD therapeutics in the region will increase considerably.

By treatment, stem cell and gene therapy, antibiotic therapy, immunoglobulin (Ig) replacement therapy, and others make the key segments in the global PIDD market. Of these, immunoglobulin replacement has been in use for the treatment of chronic ailments for the past two decades. Due to the recent developments, it is also used for the treatment of partial antibody deficiency and combined immunodeficiencies. The segment therefore emerged dominant in the market in 2014. As per TMR, immunoglobulin replacement therapy will hold on to its position as the market leader through the forecast period.

Despite, Ig replacement therapy being the most widely accepted treatment among PIDD patients, the use of antibiotics as an adjunct therapy is poised to surge in the near future. Some of the most commonly used antibiotics include penicillin, macrolides, cephalosporins, fluoroquinolones, and tetracyclines.

The demand for stem cell and gene therapy is also expected to increase during the forecast period, which in turn will augment the demand for effective PIDD treatment.

Posts navigation

Text Widget

This is a text widget. The Text Widget allows you to add text or HTML to your sidebar. You can use a text widget to display text, links, images, HTML, or a combination of these. Edit them in the Widget section of the Customizer.